International Journal of Spectroscopy

International Journal of Spectroscopy / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 308087 | 8 pages | https://doi.org/10.1155/2014/308087

New Kinetic Spectrophotometric Method for Determination of Fexofenadine Hydrochloride in Pharmaceutical Formulations

Academic Editor: Hicham Fenniri
Received27 Feb 2014
Revised16 Apr 2014
Accepted17 Apr 2014
Published29 Jun 2014

Abstract

A simple and sensitive kinetic spectrophotometric method was developed for the determination of fexofenadine hydrochloride in bulk and pharmaceutical preparations. The method is based on a kinetic investigation of the oxidation reaction of fexofenadine using alkaline potassium permanganate as an oxidizing agent at room temperature. The reaction is followed spectrophotometrically by measuring the increase of absorbance owing to the formation of manganate ion at 610 nm. The initial rate and fixed time (at 15 min) methods are utilized for construction of calibration graphs. All the reaction conditions for the proposed method have been studied. The linearity range was found to be 2.5–50.0 μg mL−1 with detection limit of 0.055 μg mL−1 for both initial rate and fixed time methods. The proposed method was applied successfully for the determination of fexofenadine in pharmaceutical formulations; the percentage recoveries were 99.98–101.96%. The results obtained were compared statistically with those obtained by the official method and showed no significant differences regarding accuracy and precision.

1. Introduction

Fexofenadine, (±)-4-[1-hydroxy-4-[4-(hydroxyl diphenylmethyl)-1-piperidinyl]butyl]-alpha, alpha-dimethyl benzene acetic acid, an active metabolite of terfenadine, is a selective histamine H1-receptor antagonist and is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria as a first-line therapeutic agent, such as loratadine and cetirizine [1]. Several methods for the determination of fexofenadine hydrochloride in pharmaceutical formulations and biological fluids have been reported including HPLC [25], spectrophotometry [59], extractive spectrophotometry and conductometry [10], spectrofluorometry [11], potentiometry [12], and capillary electrophoresis [13, 14]. Fexofenadine hydrochloride has been determined in combination with other drugs using HPLC [1519], HPTLC [20], and spectrophotometry [2123] in combined dosage forms. Fexofenadine has been determined in human plasma by HPLC with UV detection [24], fluorescence detection [25], and tandem mass spectrometry detection [2628].

Kinetic methods have certain advantages in pharmaceutical analysis regarding selectivity and elimination of additive interferences, which affect direct spectrophotometric methods. The literature is still poor in analytical assay methods based on kinetics for the determination of fexofenadine in dosage forms. Some specific advantages that the kinetic methods possess are as follows: simple and fast methods because some experimental steps such as filtration and extraction are avoided prior to absorbance measurements; high selectivity since they involve the measurement of the absorbance as a function of reaction time instead of measuring the concrete absorbance value; other active compounds present in the commercial dosage forms which may not interfere if they are resisting the chemical reaction conditions established for the proposed kinetic method, and colored and/or turbid sample background which may not possibly interfere with the determination process [29, 30].

In our study fexofenadine was found to react with permanganate in alkaline medium; the reaction yielded a bluish green manganate with a at 610 nm. This color reaction was studied for the direct spectrophotometric determination of the drug. Optimum conditions were established and the method was validated for linearity, sensitivity, accuracy, and precision. The validated method when applied to the determination of FEX in formulations yielded results which were in agreement with the label claim.

2. Experimental

2.1. Apparatus

A Jasco V-530 UV-VIS spectrophotometer (Japan) with 1 cm quartz cells was used for all absorbance measurements under the following operating conditions: scan speed medium (400 nm/min), scan range 350–700 nm, and slit width 2 nm. Spectra were automatically obtained by Jasco system software. pH measurements were made with Consort C830 (Belgium) with combined glass pH electrode.

2.2. Reagents and Materials

All chemicals and reagents used throughout this work were of analytical reagent grade and supplied by Merck (Germany) and solutions were made with doubly distilled water. Fexofenadine hydrochloride (FEX) was obtained from Chem Pharma (India). The purity of FEX was found to be 99.86% according to BP [31]. Pharmaceutical preparations containing FEX were purchased from commercial sources in the local market.

Stock solutions,  M of potassium permanganate and 1.0 M of sodium hydroxide, were prepared by dissolving the accurately weighed amounts of the pure solid in doubly distilled water. Absolute methanol was used to prepare the drug sample solution. Stock solution, 0.25 mg mL−1 of FEX, was prepared in doubly distilled water, stored in dark bottles, and kept in the refrigerator for no more than 10 days. Other concentrations of working solutions were then prepared by suitable dilution of the stock solution with water.

2.3. Procedure for Initial Rate Method

Aliquots of 2.5–50 μg mL−1 of FEX test solution (0.10–2.00 mL, 0.25 mg mL−1) were pipetted into a series of 10 mL volumetric flask. 1.0 mL of potassium permanganate solution (0.01 M) was added followed by 1 mL of sodium hydroxide solution (1.0 M) to each flask and then diluted to the volume with double distilled water at 25°C. The content of mixture of each flask was mixed well and the increase in absorbance at 610 nm was recorded as a function of time over 0–20 min against reagent blank treated similarly. The initial rate of the reaction at different concentrations was obtained from the slope of the tangent to absorbance time curves. The calibration graphs were constructed by plotting the logarithm of the initial rate of the reaction versus logarithm of molar concentration of FEX .

2.4. Procedure for Fixed Time Method

Aliquots of 2.5–50 μg mL−1 of FEX test solution (0.10–2.00 mL, 0.25 mg mL−1) were pipetted into a series of 10 mL volumetric flask. 1.0 mL of potassium permanganate solution (0.01 M) was added followed by 1 mL of sodium hydroxide solution (1.0 M) to each flask and then diluted to the volume with double distilled water at 25°C. The content of mixture of each flask was mixed well and the absorbance of each sample solution at preselected fixed time (15 min) was accurately measured and plotted against the final concentration of the drug.

2.5. Procedure for Pharmaceutical Formulations

Twenty tablets were weighted accurately and crushed to a fine powder. In the case of capsules, the contents of twenty capsules were completely evacuated from shells. An accurately weighed quantity of the powder equivalent to 25 mg of the cited drug was dissolved in 50 mL of methanol and mixed for about 15 min and then filtered through Whatman filter paper number 40. The methanol was evaporated to dryness. The remaining portion of solution was dissolved in a 100 mL volumetric flask to the volume with double distilled water to achieve a concentration of 0.25 mg mL−1. The general procedure was then followed in the concentration ranges mentioned above.

3. Results and Discussion

Potassium permanganate in alkaline medium oxidizes FEX and yields the bluish green color due to the production of manganate ion which is absorbed maximally at 610 nm as shown in Figure 1. The absorbance of the reaction product remains stable for at least 60 min. The increase in the intensity of the color by time was used as a basis for a useful kinetic method for the determination of FEX in pharmaceutical formulation.

3.1. Optimization of Reaction Conditions

The spectrophotometric properties of the colored product as well as the different experimental parameters affecting the color development and its stability were studied and optimized by changing each variable in turn, while keeping all the others constant. The effect of potassium permanganate concentration on the reaction was studied over the range  M, in the final concentration. The maximum absorbance was obtained at concentration of  M (when 1.0 mL of 0.01 M KMnO4 was added). Complete reaction between FEX and potassium permanganate takes place only in alkaline medium. The influence of the medium alkalinity was investigated between and 0.2 M sodium hydroxide. 0.1 M sodium hydroxide in the final concentration (1 mL of 1.0 M sodium hydroxide) was chosen for all subsequent experiments (Figure 2).

The effect of temperature on the reaction of FEX with KMnO4 in alkaline medium was studied at different values (20–55°C) by continuous monitoring of the absorbance at 610 nm. It was found that the reaction with KMnO4 was not affected by increasing the temperature, and the reaction at laboratory ambient temperature (25±5°C) went to completion within 15 min. The results revealed that increasing the temperature (>55°C had negative effect on the absorption values of the reaction solution.

3.2. Quantitation Methods

Because the intensity of the color increased at 610 nm with time (Figure 3), this was used as the basis for a useful kinetic method for the determination of FEX. The initial rate, rate constant, fixed absorbance, and fixed time methods [32, 33] were tested and the most suitable analytical methods were chosen regarding the applicability, sensitivity, and the values of the intercept and correlation coefficient .

3.2.1. Initial Rate Method

The initial rate of reaction would follow a pseudo order rate constant and obeyed the following rate equation: where is the reaction rate, is the absorbance, is the measuring time, is the pseudo order rate constant, is the concentration of the drug mol/L, and is the order of the reaction. A calibration curve was constructed by plotting the logarithm of the initial rate of reaction versus logarithm of drug concentration which showed a linear relationship over the concentration range of 2.5–50.0 μg mL−1 (Figure 4). The logarithmic form of the above equation is written as follows: Thus, , and the reaction is the first order () with respect to FEX concentration.

3.2.2. Rate Constant Method

The logarithm of the absorbance of reaction versus time for each concentration of FEX studied over the concentration range of 2.5–50.0 μg mL−1 (Figure 3) was calculated. Graphs of log absorbance versus time for FEX concentration in the range of 30.0–45.0 μg mL−1 (5.57 × 10−5–8.36 × 10−5 M) were plotted and all appeared to be rectilinear. Pseudo order rate constants corresponding to different FEX concentrations were calculated from the slopes multiplied by −2.303 and are presented in Figure 5. Regression of versus gave the following equation:

3.2.3. Fixed Absorbance Method

Reaction rate data were recorded for different FEX concentrations in the range 30.0–50.0 μg mL−1. A preselected value of the absorbance 0.75 was fixed and the time was measured in seconds. The reciprocal of time versus the initial concentration of FEX was plotted (Figure 6) and the following equation of calibration graph was obtained: The range of FEX concentrations giving the most satisfactory results was limited 30.0–50.0 μg mL−1 (5.57 × 10−5–9.29 × 10−5 M).

3.2.4. Fixed Time Method

At preselected fixed time, the absorbance of bluish green colored solution containing varying amounts of FEX was measured at 25°C and 610 nm. Calibration graphs were constructed by plotting the absorbance against the initial concentration of FEX at fixed time 0–30 min. The regression equations, correlation coefficients, and linear ranges are given in Table 1.


Time (min)Regression equationCorrelation coefficientLinear range (μg mL−1)

0A = 0.0058C + 0.01110.99712.5–50.0
5A = 0.0149C + 0.00280.99812.5–50.0
10A = 0.0190C + 0.00940.99932.5–50.0
15A = 0.0209C + 0.02400.99972.5–50.0
20A = 0.0221C + 0.03500.99912.5–50.0
25A = 0.0229C + 0.04950.99682.5–50.0
30A = 0.0233C + 0.06450.99432.5–50.0

A: absorbance; C: concentration.

It is clear that the slope increases with time and the most acceptable value of was obtained for a fixed time of 15 min. Therefore, the fixed time of 15 min was utilized for the assay of FEX concentration. As a result, the most acceptable values of the correlation coefficient and linear range were obtained for the initial rate (20 min) and fixed time (15 min) methods. Thus, they were used for the determination of FEX in pure form and pharmaceutical formulations.

3.3. Analytical Method Validation
3.3.1. Calibration Graph

After optimizing the reaction conditions, the fixed time was applied to the determination of FEX in pure form over the concentration range 2.5–50.0 μg mL−1. A linear relationship was found between the absorbance at and the concentration of the FEX in the mentioned range. Analysis of the data gave the regression equation shown in Table 2. Regression analysis of Beer’s law plots reveals a good correlation. The graph shows negligible intercept and is described by the regression equation, (where is the absorbance of 1 cm layer, is the slope, is the intercept, and is the concentration of the measured solution in μg mL−1) obtained by the least-squares method [34].


ParametersFEX

(nm)610
Beer’s law range ( g mL−1)2.5–50.0
Ringbom optimum concentration range ( g mL−1)10.0–40.0
Detection limit ( g mL−1)0.055
Quantification limit ( g mL−1)0.183
Molar absorptivity (L mol−1 cm−1)1.22 × 104
Stoichiometric relationship, FEX : KMnO41 : 1
Sandell’s sensitivity ( g cm−2 per 0.001 absorbance unit)0.088
Regression equationaA = 0.0209C + 0.024
Correlation coefficient, 0.9998

A = mC + b, where A is the absorbance and C is the concentration in g mL−1.
3.3.2. LOD and LOQ

The minimum level at which the investigated compound can be reliably detected (limit of detection, LOD) and quantified (limit of quantitation, LOQ) was determined experimentally for fixed time (15 min) method. The LOD was expressed as the concentration of drug that generated a response to three times of the signal to-noise (S/N) ratio, and the LOQ was 10 times of the S/N ratio. The LOD of FEX attained as defined by IUPAC [35], (where is the slope of the calibration curve and is the standard deviation of the intercept), was found to be 0.055 μg mL−1. The LOQ was also attained according to the IUPAC definition, , and was found to be 0.183 μg mL−1. Sandell’s index represents the number of micrograms or nanograms of the determinant per milliliter of a solution having an absorbance of 0.002 for the cell path length of 1 cm and is a suitable parameter for expressing and comparing the sensitivity of developed spectrophotometric method. Sandell’s sensitivity coefficient of FEX was found to be 0.088 μg cm−2 per 0.001 absorbance unit (Table 2). The high molar absorptivity of the colored product indicates the high sensitivity of the method. For more accurate analysis, Ringbom optimum concentration range was calculated [36]. Table 2 shows the values of molar absorptivity, Sandell’s sensitivity, and some analytical characteristics for fixed time (15 min) method.

3.3.3. Accuracy and Precision

The accuracy and precision of the proposed method were carried out by six determinations at four different concentrations. Percentage relative standard deviation (RSD%) as precision and percentage recovery as accuracy of the suggested methods were calculated and shown in Table 3. The values of relative standard deviations for different concentrations of FEX are determined from the calibration curves. These results of accuracy and precision show that the proposed methods have good repeatability and reproducibility. The proposed methods were found to be selective for the estimation of FEX in the presence of various tablet excipients. For this purpose, a powder blend using typical tablet excipients was prepared along with the drug and then analyzed. The recoveries were not affected by the excipients and the excipients blend did not show any absorption in the range of analysis.


MethodFEX, g mL−1RSD% Confidence limit 
(P = 0.05; n = 6)
Recovery%
TakenFoundaSD

Initial rate5.005.010.122.395.01 ± 0.13100.20
20.0020.200.200.9920.20 ± 0.22101.00
35.0034.900.280.8034.90 ± 0.3199.71
50.0050.130.140.2850.13 ± 0.15100.26

Fixed time5.005.040.132.585.04 ± 0.15100.80
20.0020.140.301.4920.14 ± 0.34100.70
35.0035.000.320.9135.00 ± 0.36100.00
50.0050.310.360.7150.31 ± 0.40100.62

Average of six determinations.
3.4. Stoichiometry of the Reaction

The stoichiometry of the reaction was studied adopting the limiting logarithmic method [37]. The ratio of the reaction between FEX and KMnO4 in alkaline medium was calculated by dividing the slope of KMnO4 curve over the slope of the drug curve (Figures 7(a) and 7(b)). It was found that the ratio was 1 : 1 (KMnO4 to FEX). The proposal pathway of the reaction is given as Scheme 1 where potassium permanganate in alkaline medium oxidizes FEX from enolic to ketonic form and yields the bluish green color due to the production of manganate ion.

308087.sch.001
3.5. Application to the Pharmaceutical Dosage Forms

The proposed techniques were applied to the tablets and capsules. The ingredients in the tablets and capsules did not interfere in the experiments. The applicability of the proposed methods for the assay of fexofenadine hydrochloride in formulations was examined by analyzing various formulations and the results tabulated in Table 4 were compared to the official HPLC method for fexofenadine hydrochloride [31] by means of - and -values at 95% confidence level. In all cases, the average results obtained by proposed methods and official method were statistically identical, as the difference between the average values had no significance at 95% confidence level. The low values of RSD show the results are reproducible. The proposed methods are simple, sensitive, and reproducible and can be used for routine analysis of fexofenadine hydrochloride in pure form and in formulations. The commonly used additives such as starch, lactose, glucose, and magnesium stearate do not interfere with the assay procedures.


FormulationLabel claim% Founda  ± SD
Proposed methods Official method [31]
Initial rateFixed time

Allergy stopb60 mg/Cap100.75 ± 0.19101.04 ± 0.21100.79 ± 0.13
t = 1.99t = 2.17t = 1.32
F = 2.14F = 2.61
120 mg/Tab101.06 ± 0.20100.12 ± 0.18101.05 ± 0.15
t = 2.05t = 1.75t = 1.28
F = 1.78F = 1.44
180 mg/Tab99.98 ± 0.18100.60 ± 0.2099.78 ± 0.14
t = 1.68 t = 1.36t = 1.79
F = 1.65F = 2.04

Fexofenadinec60 mg/Cap100.27 ± 0.15 101.00 ± 0.13 100.84 ± 0.11 
t = 1.99t = 1.00t = 1.88
F = 1.86F = 1.41

Fenadind120 mg/Tab101.96 ± 0.13 100.26 ± 0.14 99.69 ± 0.12 
t = 1.67t = 2.06t = 1.24
F = 1.17F = 1.52
180 mg/Tab100.95 ± 0.20101.08 ± 0.23100.52 ± 0.18
t = 1.70 t = 1.12 t = 1.81
F = 1.23F = 1.63

Five independent analyses. At 95% confidence level t-value is 2.776 and F-value is 6.26.
bSupplied by Pharmasyr, Syria; csupplied by Ibn-Alhaytham, Syria; dsupplied by BPI, Syria.

4. Conclusion

The developed kinetic spectrophotometric method for the determination of fexofenadine hydrochloride in bulk and pharmaceutical formulations was sensitive, accurate, and precise. The limits of detection and quantitation were 0.055 and 0.183 μg mL−1, respectively. Potassium permanganate was used as an oxidizing agent in alkaline medium. The sample recoveries from all formulations were in good agreement with their respective label claims, which suggested noninterference of formulations excipients in the estimation. The developed method has more speed and higher sensitivity as compared to reported spectrophotometric methods and has a wider range of linearity. Moreover, all the analytical reagents are inexpensive, have good shelf life, and are available in any analytical laboratory along with the lower reagents consumption leading to an environmentally friendly spectrophotometric procedure, which makes it especially suitable for routine quality control analysis work.

Conflict of Interests

There is no kind of financial gain between the authors and the mentioned corporations and identities inside the paper.

References

  1. C. S. Sean, Martindale , The Complete Drug Reference, Royal Pharmaceutical Society, Pharmaceutical Press, London, UK, 36th edition, 2009.
  2. A. R. Breier, S. C. Paim, J. Menegola, M. Steppe, and E. E. Schapoval, “Development and validation of a liquid chromatographic method for fexofenadine hydrochloride in capsules,” Journal of AOAC International, vol. 87, no. 5, pp. 1093–1097, 2004. View at: Google Scholar
  3. H. M. Maher, M. A. Sultan, and I. V. Olah, “Development of validated stability-indicating chromatographic method for the determination of fexofenadine hydrochloride and its related impurities in pharmaceutical tablets,” Chemistry Central Journal, vol. 5, article 76, 2011. View at: Publisher Site | Google Scholar
  4. M. S. Arayne, N. Sultana, H. Shehnaz, and A. Haider, “RP-HPLC method for the quantitative determination of fexofenadine hydrochloride in coated tablets and human serum,” Medicinal Chemistry Research, vol. 20, no. 1, pp. 55–61, 2011. View at: Publisher Site | Google Scholar
  5. I. Kozan, I. M. Palabiyik, E. Karacan, and F. Onur, “Spectrophotometric and high performance liquid chromatographic determination of fexofenadine hydrochloride in pharmaceutical formulations,” Turkish Journal of Pharmaceutical Sciences, vol. 5, no. 3, pp. 175–189, 2008. View at: Google Scholar
  6. A. A. Gazy, H. Mahgoub, F. A. El-Yazbi, M. A. El-Sayed, and R. M. Youssef, “Determination of some histamine H1-receptor antagonists in dosage forms,” Journal of Pharmaceutical and Biomedical Analysis, vol. 30, no. 3, pp. 859–867, 2002. View at: Publisher Site | Google Scholar
  7. K. Suresh Kumar, V. Ravichandran, M. K. Mohan Maruga Raja, R. Thyagu, and A. Dharamsi, “Spectrophotometric determination of Fexofenadine hydrochloride,” Indian Journal of Pharmaceutical Sciences, vol. 68, no. 6, pp. 841–842, 2006. View at: Publisher Site | Google Scholar
  8. S. J. Rajput and P. R. Parekh, “Spectrophotometric determination of fexofenadine hydrochloride in bulk drug and in its dosage form,” Eastern Pharmacist, vol. 44, no. 527, pp. 101–103, 2001. View at: Google Scholar
  9. P. V. Polawar, U. D. Shivhare, K. P. Bhusari, and V. B. Mathur, “Development and validation of spectrophotometric method of analysis for fexofenadine,” Research Journal of Pharmacy and Technology, vol. 1, no. 4, pp. 539–541, 2008. View at: Google Scholar
  10. S. Ashour, M. Khateeb, and R. Mahrouseh, “Extractive spectrophotometric and conductometric methods for determination of fexofenadine hydrochloride in pharmaceutical dosage forms,” Pharmaceutica Analytica Acta, vol. S2, pp. 1–6, 2013. View at: Google Scholar
  11. Z. A. Alothman, N. Bukhari, S. Haider, S. M. Wabaidur, and A. A. Alwarthan, “Spectrofluorimetric determination of fexofenadine hydrochloride in pharmaceutical preparation using silver nanoparticles,” Arabian Journal of Chemistry, vol. 3, no. 4, pp. 251–255, 2010. View at: Publisher Site | Google Scholar
  12. M. N. Abbas, A. A. Fattah, and E. Zahran, “A novel membrane sensor for histamine H1-receptor antagonist fexofenadine,” Analytical Sciences, vol. 20, no. 8, pp. 1137–1142, 2004. View at: Publisher Site | Google Scholar
  13. P. Mikuš, I. Valášková, and E. Havránek, “Determination of fexofenadine in tablets by capillary electrophoresis in free solution and in solution with cyclodextrins as analyte carriers,” Drug Development and Industrial Pharmacy, vol. 31, no. 8, pp. 795–801, 2005. View at: Publisher Site | Google Scholar
  14. A. R. Breier, S. S. Garcia, A. Jablonski, M. Steppe, and E. E. S. Schapoval, “Capillary electrophoresis method for fexofenadine hydrochloride in capsules,” Journal of AOAC International, vol. 88, no. 4, pp. 1059–1063, 2005. View at: Google Scholar
  15. S. S. Zarapkar, N. P. Bhandari, and U. P. Halkar, “Simultaneous determination of Fexofenadine Hydrochloride and Pseudoephedrine Sulfate in pharmaceutical dosage by reverse phase high performance liquid chromatography,” Indian Drugs, vol. 37, no. 9, pp. 421–425, 2000. View at: Google Scholar
  16. T. Radhakrishna and G. O. Reddy, “Simultaneous determination of fexofenadine and its related compounds by HPLC,” Journal of Pharmaceutical and Biomedical Analysis, vol. 29, no. 4, pp. 681–690, 2002. View at: Publisher Site | Google Scholar
  17. H. Vekaria, V. Limbasiya, and P. Patel, “Development and validation of RP-HPLC method for simultaneous estimation of montelukast sodium and fexofenadine hydrochloride in combined dosage form,” Journal of Pharmacy Research, vol. 6, no. 1, pp. 134–139, 2013. View at: Publisher Site | Google Scholar
  18. S. Karakuş, İ. Küçükgüzel, and Ş. Güniz Küçükgüzel, “Development and validation of a rapid RP-HPLC method for the determination of cetirizine or fexofenadine with pseudoephedrine in binary pharmaceutical dosage forms,” Journal of Pharmaceutical and Biomedical Analysis, vol. 46, no. 2, pp. 295–302, 2008. View at: Publisher Site | Google Scholar
  19. M. S. Arayne, N. Sultana, A. Z. Mirza, and F. A. Siddiqui, “Simultaneous determination of gliquidone, fexofenadine, buclizine, and levocetirizine in dosage formulation and human serum by RP-HPLC,” Journal of Chromatographic Science, vol. 48, no. 5, pp. 382–385, 2010. View at: Publisher Site | Google Scholar
  20. S. S. Tandulwadkar, S. J. More, A. S. Rathore, A. R. Nikam, L. Sathiyanarayanan, and R. Kakasaheb, “Method development and validation for the simultaneous determination of fexofenadine hydrochloride and montelukast sodium in drug formulation using normal phase high-performance thin-layer chromatography,” ISRN Analytical Chemistry, vol. 2012, Article ID 924185, 7 pages, 2012. View at: Publisher Site | Google Scholar
  21. H. Mahgoub, A. A. Gazy, F. A. El-Yazbi, M. A. El-Sayed, and R. M. Youssef, “Spectrophotometric determination of binary mixtures of pseudoephedrine with some histamine H1-receptor antagonists using derivative ratio spectrum method,” Journal of Pharmaceutical and Biomedical Analysis, vol. 31, no. 4, pp. 801–809, 2003. View at: Publisher Site | Google Scholar
  22. R. M. Maggio, P. M. Castellano, S. E. Vignaduzzo, and T. S. Kaufman, “Alternative and improved method for the simultaneous determination of fexofenadine and pseudoephedrine in their combined tablet formulation,” Journal of Pharmaceutical and Biomedical Analysis, vol. 45, no. 5, pp. 804–810, 2007. View at: Publisher Site | Google Scholar
  23. H. J. Vekaria, K. S. Muralikrishna, and G. F. Patel, “Development and validation of spectrophotometric method for estimation of fexofenadine hydrochloride and montelukast sodium in combined dosage form,” Pharm Analysis & Quality Assurance, vol. 4, pp. 197–199, 2011. View at: Google Scholar
  24. M. Miura, T. Uno, T. Tateishi, and T. Suzuki, “Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography,” Journal of Pharmaceutical and Biomedical Analysis, vol. 43, no. 2, pp. 741–745, 2007. View at: Publisher Site | Google Scholar
  25. T. Uno, N. Yasui-Furukori, T. Takahata, K. Sugawara, and T. Tateishi, “Liquid chromatographic determination of fexofenadine in human plasma with fluorescence detection,” Journal of Pharmaceutical and Biomedical Analysis, vol. 35, no. 4, pp. 937–942, 2004. View at: Publisher Site | Google Scholar
  26. E. A. Ö. Işleyen, T. Özden, S. Özilhan, and S. Toptan, “Quantitative determination of fexofenadine in human plasma by HPLC-MS,” Chromatographia, vol. 66, no. 1, pp. 109–113, 2007. View at: Publisher Site | Google Scholar
  27. N. Yamane, Z. Tozuka, Y. Sugiyama, T. Tanimoto, A. Yamazaki, and Y. Kumagai, “Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 858, no. 1-2, pp. 118–128, 2007. View at: Publisher Site | Google Scholar
  28. R. V. Nirogi, V. N. Kandikere, M. Shukla, K. Mudigonda, S. Maurya, and P. Komarnei, “Quantification of fexofenadine in human plasma by liquid chromatography couple to electrospray tandem mass spectrometry using mosapride as internal standard,” Biomedical Chromatography, vol. 21, no. 2, pp. 209–216, 2007. View at: Publisher Site | Google Scholar
  29. D. Pérez-Bendito, A. Gómez-Hens, and M. Silva, “Advances in drug analysis by kinetic methods,” Journal of Pharmaceutical and Biomedical Analysis, vol. 14, no. 8-10, pp. 917–930, 1996. View at: Publisher Site | Google Scholar
  30. S. Ashour, “New kinetic spectrophotometric method for determination of atorvastatin in pure and pharmaceutical dosage forms,” Pharmaceutica Analytica Acta, vol. 4, no. 5, pp. 1–6, 2013. View at: Google Scholar
  31. British Pharmacopœia, Her Majesty Stationery Officer, London, UK, 2013.
  32. M. Kopanica, V. Satra, K. Echschlager, I. Rorsak, Z. Koduys, and K. Sandr, Eds., Kinetic Methods in Chemical Analysis, Elsevier, Amsterdam, The Netherlands, 1983.
  33. D. Persez-Bendit and M. Silva, Kinetic Methods in Analytical Chemistry, chapter 11, John Wiley & Sons, New York, NY, USA, 1988.
  34. J. N. Miller and J. C. Miller, Statistics and Chemometrics for Analytical Chemistry, Prentice Hall, London, UK, 5th edition, 2005.
  35. G. L. Long and J. D. Winefordner, “Limit of detection: a closer look at the IUPAC definition,” Analytical Chemistry, vol. 55, no. 7, pp. 712–724, 1983. View at: Google Scholar
  36. A. Ringbom, “Über die Genauigkeit der colorimetrischen Analysenmethoden I.,” Zeitschrift für Analytische Chemie, vol. 115, no. 9-10, pp. 332–343, 1939. View at: Publisher Site | Google Scholar
  37. J. Rose, Advanced Physico-Chemical Experiments, Pittman, London, UK, 1964.

Copyright © 2014 Safwan Ashour and Mouhammed Khateeb. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1634 Views | 527 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.